Lab
Laboratory Corporation of America
Laboratory Corporation of America was paid $2.46M by Medicaid between Oct 2021 and Dec 2024, across 54 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 73% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA
SOUTH BEND, IN 46628
SOUTH BEND, IN 46628
33aNPI1043891336assigned 04/19/2021
33bProvider typeClinical Medical Laboratory
28Total paid$2.46M
24GClaims106,776
24DCodes billed54
24AFirst – last monthOct 2021 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Indiana
Rank by total paid#10 of 66
Median peer was paid$53K
This provider vs. median47×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 20,625 | $556K | |
| 2022 | 56,907 | $1.73M | |
| 2023 | 15,739 | $93K | |
| 2024incomplete | 13,505 | $85K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 73% | 36,091 | 27,517 | $1.79M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 17% | 27,115 | 20,298 | $410K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.1% | 9,846 | 8,700 | $51K |
| 87088 | <1% | 4,136 | 3,699 | $21K | |
| 87186 | <1% | 2,875 | 2,594 | $17K | |
| 82728 | <1% | 2,633 | 2,328 | $16K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,296 | 2,549 | $16K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 242 | 210 | $12K |
| 87077 | <1% | 2,446 | 2,177 | $12K | |
| 87150 | <1% | 421 | 406 | $11K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 468 | 404 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 468 | 404 | $11K |
42 more codes
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,650 | $10K |
| 83550 | <1% | 2,291 | $9K | |
| 83540 | <1% | 2,300 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 431 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 392 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 125 | $5K |
| 87081 | <1% | 974 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 145 | $5K |
| 81001 | <1% | 1,817 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 237 | $4K |
| 82607 | <1% | 579 | $3K | |
| 84439 | <1% | 800 | $3K | |
| 82378 | <1% | 300 | $3K | |
| 83615 | <1% | 942 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 628 | $2K |
| 80177 | <1% | 201 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 531 | $1K |
| 82784 | <1% | 194 | $1K | |
| 82746 | <1% | 179 | $1K | |
| 86334 | <1% | 142 | $883.10 | |
| 85379 | <1% | 163 | $800.04 | |
| 87070 | <1% | 125 | $759.58 | |
| 80061 | Lipid panel | <1% | 121 | $664.73 |
| 81003 | <1% | 339 | $646.61 | |
| 80050 | General health panel | <1% | 17 | $520.40 |
| 84165 | <1% | 183 | $453.63 | |
| 84702 | <1% | 52 | $322.75 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 60 | $277.58 |
| 87205 | <1% | 71 | $219.80 | |
| 85027 | <1% | 68 | $210.31 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 61 | $208.51 |
| 84144 | <1% | 27 | $203.36 | |
| 84155 | <1% | 201 | $138.02 | |
| 83735 | <1% | 45 | $132.65 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 90 | $126.67 |
| 85046 | <1% | 44 | $118.17 | |
| 85045 | <1% | 53 | $109.01 | |
| 82570 | <1% | 13 | $59.09 | |
| 85610 | <1% | 20 | $49.77 | |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 80 | $45.29 |
| 85652 | <1% | 35 | $44.12 | |
| 84156 | <1% | 13 | $30.33 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.